TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05301023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized antibiotic therapy
Description: Individualized antibiotic therapy is based on the duration of illness after treatment initiation, as the antibiotic therapy can be stopped three days after the participant has become healthy. The participant is classified as healthy if he/she is afebrile (\<38.0 °C), has experienced significant clinical improvement, and have no flank pains or dysuria.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard antibiotic therapy
Description: Standard antibiotic therapy is 10 days of antibiotic therapy regardless of the duration of illness after treatment initiation.
Study: NCT05943067

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CD45RA depleted donor lymphocyte infusion (DLI)
Description: CD45RA depleted donor lymphocyte infusion (DLI) after TCRα/β depleted haploidentical HCT
Study: NCT05282472

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CPET without mask
Description: Regular cardiopulmonary exercise tests were applied to all participants in phase 1.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CPET with mask
Description: A 3-layer surgical mask was placed on CPET device's mask and was fixed with a CPET tribune. In phase 2, as using this combined (surgical mask and device's mask) masks, CPETs were performed in all participants again, after 48 hours.
Study: NCT06047743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternating unilateral Isometric Handgrip Exercise
Description: Participants (n=19) will be performing alternating unilateral Isometric Handgrip exercises using a dynamometer for 3-5 days a week for a total duration of 8 weeks. The participant will be seated with their elbow resting on the armrest and wrists off the supporting surface. A single session will consist of 4 sets of 30%MVC (calculated by dynamometer) of handgrip exercise with a maximum 2 minutes contraction time/ hold time followed by a rest period/ recovery period of 1 minute during each set.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dominant knee extension Isometric Exercise
Description: Participants enrolled in this group will be performing dominant leg isometric knee extension. The knee will be 35° flexed from a fully extended position when performing isometric knee extension using a hand-held dynamometer retrained by a belt. The intervention duration will be 8 weeks. A single session will consist of performing 4 sets of 30% MVC (calculated using a dynamometer) of unilateral knee extension isometrics with a maximum 2 minutes contraction time/ hold time followed by a rest/ recovery period of 1 minute during each set.
Study: NCT06504329

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MCAT + subepithelial connective tissue graft
Description: After the tunnel is prepared using the MCAT technique, a connective tissue graft harvested from the palate will be placed into the tunnel with guiding sutures and secured in place. The flap will be advanced coronally to cover the connective tissue, ensuring primary closure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MCAT + enamel matrix derivate
Description: Participants in the Experimental groups will receive Emdogain as part of the treatment protocol. Emdogain will be applied in gel form with a dosage of 0.15 ml. It will be administered in conjunction with the modified coronally advanced tunnel (MCAT) technique. Emdogain will be used as an enamel matrix derivative to promote periodontal tissue regeneration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MCAT + subepithelial connective tissue graft + enamel matrix derivative
Description: As part of the treatment protocol, participants will receive Emdogain in addition to the connective tissue graft. Emdogain will be applied in gel form at a dosage of 0.15 ml. It will be used in conjunction with the Modified Coronally Advanced Tunnel (MCAT) technique. Emdogain, an enamel matrix derivative, will be used to support periodontal tissue regeneration.
Study: NCT06504485

Intervention type: DRUG
Intervention: Bulevirtide
Description: dose of 2 mg/day subcutaneously
Study: NCT06394401

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BAL:GLU
Description: 80 g glucose consumed during steady-state exercise following 48 hours of consuming an energy balance diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BAL:GLU+FRU
Description: 53 g glucose plus 27 g fructose consumed during steady-state exercise following 48 hours of consuming an energy balance diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DEF:GLU
Description: 80 g glucose consumed during steady-state exercise following 48 hours of consuming an energy balance diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DEF:GLU+FRU
Description: 53 g glucose plus 27 g fructose consumed during steady-state exercise following 48 hours of consuming an energy balance diet
Study: NCT05938777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Stage-Matched Intervention
Description: The proposed intervention will be non-Stage-Matched that uses different Processes of Change as strategies to change the physical exercise behavior.
Study: NCT06495944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dazucorilant
Description: 75 mg soft gelatin capsules formulation for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 100 mg capsules for oral administration
Study: NCT05346783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJO-083
Description: Diquafosol ophthalmic sodium solution, 1 drop 3 times a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle)
Description: 1 drop 6 times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diquafosol ophthalmic sodium solution 3%
Description: Diquafosol ophthalmic sodium solution, 1 drop 6 times a day
Study: NCT05336110

Intervention type: OTHER
Intervention: Postponing surgery
Description: Postponing surgery for patients with Sars-cov-2 infection
Study: NCT04971213

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non invasive ventilation
Description: Emergency and transport ventilator (Monnal T60, Airliquide, Antony, France)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula heated and humidified oxygen
Description: AirVO2 device (Fisher and Paykel, New Zealand)
Study: NCT05739292

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EuNmCV-5
Description: 0.5mL single intramuscular dose on Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menveo
Description: 0.5mL single intramuscular dose on Day 0
Study: NCT05476081

Intervention type: DRUG
Intervention: Aspirin
Description: Aspirin (100-300 mg) administered for 21-90 days in combination with another antiplatelet treatment
Study: NCT04661904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation (cTBS)
Description: Our active treatment will consist of 600 pulses per session, delivered over the right dorsolateral prefrontal cortex at 80% of resting motor threshold (RMT). Every session cTBS consists of 50 Hz triplets of pulses delivered at 5 Hz for 40 seconds for a total of 600 pulses. Every set simulation includes 3 sessions. All enrolled patient in the cTBS group will receive 1 set simulation per day with an intersession interval (ISI) of over 30 minutes during the hospitalization after the surgery. The first set of stimulation will be given at 4 hours after the end of surgery on the day of surgery. The other sets of stimulation will be given at 8 am, 8:30 am and 9:00 am on postoperative day 1,2 and 3, respectively.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: The sham stimulation group will receive a sham cTBS (600 pulses per session, 3 sessions per day, ISI ≥ 30mins, 4 days) with the coil set at 90 against the skull. The first set of stimulation will be given at 4 hours after the end of surgery on the day of surgery. The other sets of stimulation will be given at 8 am, 8:30 am and 9:00 am on postoperative day 1,2 and 3, respectively.
Study: NCT05476081

Intervention type: DRUG
Intervention: Clopidogrel
Description: Clopidogrel (75-600 mg) administered for 21-90 days in combination with another antiplatelet treatment

Intervention type: DRUG
Intervention: Ticagrelor
Description: Ticagrelor (90-180 mg) administered for 21-90 days in combination with another antiplatelet treatment
Study: NCT06354855

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group is doing breathing exercises while watching videos
Description: Group is doing breathing exercises while watching videos: A video consisting of 30-minute exercises will be shot for these patients. And each patient will be asked to do the breathing exercise for 30 minutes by watching this video.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medium pace walking group
Description: Medium pace walking group: 30 minutes daily. Walking at a moderate pace is required. Physical activity levels will be monitored with the ActiGraph GT3X+ Accelerometer.
Study: NCT06645886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KQB198
Description: Oral KQB198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KQB198
Description: Oral KQB198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KQB198
Description: Oral KQB198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KQB198
Description: Oral KQB198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KQB198
Description: Oral KQB198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KQB198
Description: Oral KQB198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Oral dasatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Oral dasatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Oral dasatinib
Study: NCT05304585

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastography
Description: Undergo MRI
Study: NCT05103358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-sirolimus
Description: Prospective phase 2, open-label, multi-institutional basket trial to determine the efficacy and safety of nab-sirolimus administered by IV infusion to patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-sirolimus
Description: Prospective phase 2, open-label, multi-institutional basket trial to determine the efficacy and safety of nab-sirolimus administered by IV infusion to patients
Study: NCT05033314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 MG
Description: Rivaroxaban 10mg PO daily as thromboprophylaxis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo daily
Study: NCT06059560

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional therapy
Description: Intensive nutritional therapy based on real world therapy

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional therapy
Description: Intensive nutritional therapy based on real world therapy
Study: NCT05304585

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastography
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastography
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study: NCT03814135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hipnos 3
Description: 1 tablet, oral, once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hipnos 5
Description: 1 tablet, oral, once a day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hipnos 5 Placebo
Description: 1 tablet, oral, once a day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hipnos 5 Placebo
Description: 1 tablet, oral, once a day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hipnos 3 Placebo
Description: 1 tablet, oral, once a day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hipnos 3 Placebo
Description: 1 tablet, oral, once a day.
Study: NCT04859192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gamified flipped classroom
Description: moodle will be gamified
Study: NCT06604429

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: aerobic exercises in form of cycle ergometer training (Each girl started session with a 5 min of warm-up. The exercise phase is performed at 65-75% of age-predicted peak heart rate using an orbitrack device for 20 minutes). Finally, a 5 min cool-down period is permitted, the total session that would be applied about 30 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: aerobic exercises in form of cycle ergometer training (Each girl started session with a 5 min of warm-up. The exercise phase is performed at 65-75% of age-predicted peak heart rate using an orbitrack device for 20 minutes). Finally, a 5 min cool-down period is permitted, the total session that would be applied about 30 min.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet Advice
Description: Adolescent girls participated in the study receive diet advices based on a balanced low calorie diet (1500 Kcal)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Advice
Description: Adolescent girls participated in the study receive diet advices based on a balanced low calorie diet (1500 Kcal)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality exercise
Description: Virtual reality game exercise involves 25 min of exercise where adolescent girl immersed in the game and did physical activities for the upper and lower extremities according to the game's requirements, and finally a 5 min cool-down part to lower the heart rate and end the session with static flexibility routines, the total session that would be applied about 30 min of Virtual reality exercises.
Study: NCT06397911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB825
Description: The study treatment will be administered as 5 SC doses in total 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study treatment will be administered as 5 SC doses in total 12 weeks
Study: NCT05961371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Twice weekly resistance training progressing to 5 sets of 5 repetitions of 80-90% of one repetition maximum.
Study: NCT06622044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vision therapy group
Description: accommodation and vergence exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prism
Description: wearing prism glasses
Study: NCT06680921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0270
Description: Experimental

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus (Afinitor®)
Description: Experimental and Active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (Afinitor®)
Description: Experimental and Active comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane tablets
Description: Active Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant injection
Description: Active Comparator
Study: NCT06676280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Patients will take aspirin 100 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Patients will take aspirin 100 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-intensity statin
Description: Statin intensity is defined as 2018 Cholesterol Clinical Practice Guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-intensity statin
Description: Statin intensity is defined as 2018 Cholesterol Clinical Practice Guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guideline-directed statin therapy
Description: as 2018 Cholesterol Clinical Practice Guidelines.
Study: NCT05071352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam
Description: Nefopam will be administered as an initial dose of 20 mg IV dose infused over 15 minutes then, as continuous infusion of 5 mg/hr for 24 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care in the ICU for assessment and management of pain, sedation, and delirium.
Description: In our protocol we use analgiosedation approach (an opioid is used before a sedative to reach the sedation goal), targeting light sedation using richmond agitation sedation scale (RASS) score -1 to 0, and assess delirium using confusion assessment method for the ICU (CAM-ICU).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care in the ICU for assessment and management of pain, sedation, and delirium.
Description: In our protocol we use analgiosedation approach (an opioid is used before a sedative to reach the sedation goal), targeting light sedation using richmond agitation sedation scale (RASS) score -1 to 0, and assess delirium using confusion assessment method for the ICU (CAM-ICU).
Study: NCT05674201

Intervention type: COMBINATION_PRODUCT
Intervention: Propofol-Dexmedetomidine
Description: Propofol-Dexmedetomidine AND Propofol-Remifentanil

Intervention type: COMBINATION_PRODUCT
Intervention: Propofol-Dexmedetomidine
Description: Propofol-Dexmedetomidine AND Propofol-Remifentanil
Study: NCT06313177

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: syndesmosis fixation with screws
Description: syndesmosis fixation with Syndesmotic screw in neutral position versus maximum ankle dorsiflexion in ankle fracture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: syndesmosis fixation with screws
Description: syndesmosis fixation with Syndesmotic screw in neutral position versus maximum ankle dorsiflexion in ankle fracture
Study: NCT04603391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dl-Methylphenidate plus Cannabidiol
Description: Subjects will be administered one 10 mg tablet of dl-methylphenidate (Ritalin®) plus 7.5 mL Epidiolex® solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dl-Methylphenidate plus Cannabidiol
Description: Subjects will be administered one 10 mg tablet of dl-methylphenidate (Ritalin®) plus 7.5 mL Epidiolex® solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dl-Methylphenidate plus Cannabidiol Placebo solution
Description: Subjects will be administered one 10 mg tablet of dl-methylphenidate (Ritalin®) plus 7.5 mL of Epidiolex® placebo solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dl-Methylphenidate plus Cannabidiol Placebo solution
Description: Subjects will be administered one 10 mg tablet of dl-methylphenidate (Ritalin®) plus 7.5 mL of Epidiolex® placebo solution
Study: NCT04980313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xenogenic collagen matrix
Description: Use of xenogenic collagen matrix for the maintenance of buccal soft tissues around immediate dental implantes into extraction sockets.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous connective tissue graft
Description: Use of connective tissue graft for the maintenance of buccal soft tissues around immediate dental implantes into extraction sockets.
Study: NCT05688319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-Solving Training
Description: Within the scope of the study, problem-solving training was conducted for the mothers in the experimental group in the study once a week for 10 weeks. The duration of each training session was 60-90 minutes.
Study: NCT06480188

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: deep brain stimulation
Description: Group A was the GPi-DBS stimulation group； Group B was the STN-DBS stimulation group
Study: NCT05412199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percussion Massage Therapy
Description: Individuals in the percussion massage therapy group will get 3 minutes of percussion massage therapy on the hamstring and gastrocnemius muscles along the origo-insertion in the mid-frequency range.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graston
Description: Instrument-assisted soft tissue mobilization will be used on the hamstring and gastrocnemius muscles along the 5-minute origo insertion line in the Graston group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Stretching
Description: Dynamic stretching exercises for the hamstring and gastrocnemius muscles will be performed in the dynamic stretching exercise group.
Study: NCT06335719

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BES
Description: Nerve biopsies during surgery + brief electrical stimulation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care surgery
Description: Nerve biopsies during surgery - no brief electrical stimulation therapy